B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Globus Medical, Inc. Class A Common Stock (NY: GMED )

83.10 +0.47 (+0.57%)
Official Closing Price Updated: 7:00 PM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 Next >
16 Analysts Have This To Say About Globus Medical
Via Benzinga
Inari Medical Stock Gets RS Rating Upgrade
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72. 
Via Investor's Business Daily
Should you consider GLOBUS MEDICAL INC - A (NYSE:GMED) for high growth investing?
Unlocking the high Growth Potential of GLOBUS MEDICAL INC - A (NYSE:GMED). 
Via Chartmill
Novocure Stock Earns 96 RS Rating
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73. 
Via Investor's Business Daily
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
Evaluating Globus Medical: Insights From 11 Financial Analysts
Via Benzinga
What 7 Analyst Ratings Have To Say About Globus Medical
Via Benzinga
The Analyst Verdict: Globus Medical In The Eyes Of 7 Experts
Via Benzinga
NYSE:GMED is showing good growth, while it is not too expensive.
In the world of growth stocks, NYSE:GMED shines as a value proposition. 
Via Chartmill
Despite its growth, NYSE:GMED remains within the realm of affordability.
GLOBUS MEDICAL INC - A (NYSE:GMED) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
CVS Health, Johnson Controls And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Globus Medical (GMED) Q3 2024 Earnings Call Transcript
GMED earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Looking Into Globus Medical's Recent Short Interest
Via Benzinga
A Glimpse Into The Expert Outlook On Globus Medical Through 8 Analysts
Via Benzinga
Looking Into Globus Medical's Recent Short Interest
Via Benzinga
While growth is established for NYSE:GMED, the stock's valuation remains reasonable.
While growth is established for NYSE:GMED, the stock's valuation remains reasonable. 
Via Chartmill
Investors should take note of NYSE:GMED, a growth stock that remains attractively priced.
GLOBUS MEDICAL INC - A (NYSE:GMED) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
What 8 Analyst Ratings Have To Say About Globus Medical
Via Benzinga
Globus Medical (GMED) Q2 2024 Earnings Call Transcript
GMED earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GMED Stock Earnings: Globus Medical Beats EPS, Beats Revenue for Q2 2024
GMED stock results show that Globus Medical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
NYSE:GMED is showing decent growth, but is still valued reasonably.
NYSE:GMED, a growth stock which is not overvalued. 
Via Chartmill
Peering Into Globus Medical's Recent Short Interest
Via Benzinga
Where Globus Medical Stands With Analysts
Via Benzinga
NYSE:GMED is not too expensive for the growth it is showing.
Looking for growth without the hefty price tag? Consider NYSE:GMED. 
Via Chartmill
For those who appreciate growth without the sticker shock, NYSE:GMED is worth considering.
GLOBUS MEDICAL INC - A (NYSE:GMED) is showing decent growth, but is still valued reasonably. 
Via Chartmill
Staar Surgical Stock Earns RS Rating Upgrade
On Thursday, lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 87 from 77. 
Via Investor's Business Daily
Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React
U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Stryker Stock Sees RS Rating Treks Higher To 71
Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.